About this trial
H22 - Unconscious Mind Training and Memory Encoding
Phase 2.1 in progress.
The core problem this clinical trial, H22, seeks to address is the pervasive challenge of modifying deeply ingrained, often unconscious, unwanted behaviors within the general population. Many individuals struggle with habits or actions that negatively impact quality of life, productivity, or well-being, yet conventional methods often fall short due to the unconscious nature of these behaviors.
Specifically, the trial aims to investigate the efficacy of H22, a novel intervention designed to engage and train the unconscious mind, in mitigating these unwanted behaviors. The central hypothesis guiding this research is that H22 training will empower volunteers to significantly reduce the frequency and intensity of identified unwanted behaviors.
Phase 1 Results:
The trial took place in Shagamu, Nigeria, between July 25, 2026, and August 7, 2026. The study monitored 20 participants over a 14-day intervention period, evaluating their baseline assessment scores, end-of-week progress across Weeks 1 and 2, and their decisions regarding whether to continue integrating Study H22 into daily life.
All 20 enrolled participants completed the full 14 days, yielding a 100% study retention rate. Participant scores improved significantly over the 14 days, increasing from a baseline average of 14.37 to 63.00 at Week 1, and reaching 99.40 by Week 2. At the conclusion of the trial, 85% of participants (17 of 20) chose to continue Study H22 in daily life.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Can read and write
Willing and able to follow the requirements of the protocol
Disqualifiers
None
Trial design
Single group
Treatments tested in this trial
Intervention H22
BehavioralUnconscious Mind Training.
Treatment groups
Trial outcomes
Primary outcomes
Proportion of volunteers achieving measurable improvements with unconscious training following a two-week treatment protocol.
Compare the number of participants experiencing treatment-related adverse events versus those with positive treatment outcomes.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Dream Video LLC
Lead sponsor
Dream Holdings Research
Collaborator